Incyte (INCY)
(Delayed Data from NSDQ)
$57.05 USD
0.00 (0.00%)
Updated May 15, 2024 04:00 PM ET
After-Market: $57.79 +0.74 (1.30%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.05 USD
0.00 (0.00%)
Updated May 15, 2024 04:00 PM ET
After-Market: $57.79 +0.74 (1.30%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum D VGM
Zacks News
Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook
by Zacks Equity Research
Incyte Corporation (INCY) reported fourth-quarter earnings of 15 cents beating the Zacks Consensus Estimate of 14 cents.
Lilly's Olumiant Gets Marketing Authorization in Europe
by Zacks Equity Research
Eli Lilly and Company (LLY) along with its partner Incyte Corporation (INCY) announced that the European Commission has granted marketing authorization to once-daily baricitinib in Europe.
The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences
What's in Store for Avis Budget (CAR) this Earnings Season?
by Zacks Equity Research
Avis Budget Group Inc. (CAR) is scheduled to report fourth-quarter 2016 results after market closes on Feb 15.
Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies
by Zacks Equity Research
Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies
VASCO (VDSI) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
VASCO Data Security International Inc. (VDSI) is set to report fourth-quarter 2016 results after markets close on Feb 14.
Should You Sell Incyte (INCY) Before Earnings?
by Zacks Equity Research
Incyte (INCY) looks like an exciting pick for investors as it is poised to beat at earnings season.
Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report fourth-quarter 2016 results on Feb 16, before the opening bell.
Will Zoetis (ZTS) Disappoint Estimates This Earnings Season?
by Zacks Equity Research
Zoetis Inc. (ZTS) is scheduled to report fourth-quarter and full year 2016 results on Feb 16 before the market opens.
5 Toxic Stocks to Dump or Play Short for Gains
by Zacks Equity Research
Inflated price of the toxic stocks can be ascribed to either an irrational exuberance associated with them or some serious fundamental lacuna.
5 Drug Stocks Poised to Beat Earnings Estimates in Q4
by Arpita Dutt
Medical is one of the few sectors that has consistently recorded earnings growth over the last 4 quarters. Here is a look at 5 pharma and biotech stocks that look set to beat Q4 earnings estimates.
Can Prothena (PRTA) Pull a Surprise This Earnings Season?
by Zacks Equity Research
Prothena Corporation plc (PRTA) is scheduled to report fourth-quarter 2016 results on Feb 14 after the market closes.
Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Gilead Sciences Inc. (GILD ) is scheduled to report fourth-quarter 2016 results on Feb 7, after the market closes.
GW Pharmaceuticals (GWPH) Q1 Earnings: What's in Store?
by Zacks Equity Research
GW Pharmaceuticals plc (GWPH) is scheduled to report first-quarter fiscal 2017 results on Feb 7, before the opening bell.
Mallinckrodt (MNK) Earnings This Quarter: Stock to Disappoint?
by Zacks Equity Research
Mallinckrodt plc (MNK) is set to report results for the quarter ended Dec. 30, 2016 on Feb 7.
Incyte and Calithera Enter into Deal for Oncology Candidate
by Zacks Equity Research
Incyte Corporation (INCY) and Calithera Biosciences, Inc. (CALA) entered into a global collaboration and license agreement for research, development and commercialization of Calithera's CB-1158 in hematology and oncology.
Calithera Biosciences (CALA) In Focus: Stock Jumps 46.7%
by Zacks Equity Research
Calithera Biosciences, Inc. (CALA) moved big last session, as its shares jumped almost 47% on the day.
5 Toxic Stocks to Dump or Play Short Now
by Zacks Equity Research
Higher price of the toxic stocks can be attributed to either an irrational exuberance associated with them or some serious fundamental lacuna.
Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended
by Zacks Equity Research
Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced that the FDA has extended the time to review the company's NDA for baricitinib for the treatment of rheumatoid arthritis (RA).
4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal
by Arpita Dutt
Takeda to Buy ARIAD, More M&As to Follow in Biotech Sector?
Incyte/Merck to Start More Epacadostat-Keytruda Studies
by Zacks Equity Research
Incyte (INCY) and Merck (MRK) announced that they have decided to initiate additional pivotal studies on epacadostat, in combination with Merck's Keytruda.
Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
Incyte Treats First Patient in Phase II GVHD Study on Jakafi
by Zacks Equity Research
Incyte Corporation (INCY) announced that the first patient has been treated in the pivotal phase II REACH-1 study assessing its marketed drug Jakafi, in combination with corticosteroids, for the treatment of GVHD.
Two Key FDA Decisions to Watch Out for in January 2017
by Arpita Dutt
Incyte (INCY) and Synergy (SGYP) have important regulatory events coming up this month.
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech